99 studies found for:    "neurofibromatosis type 2" OR "neurofibromatosis"
Show Display Options
Rank Status Study
1 Active, not recruiting Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Vestibular Schwannoma;   Neurofibromatosis Type 2
Intervention: Drug: Endostatin
2 Recruiting Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas
Intervention: Drug: Axitinib
3 Active, not recruiting Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Condition: Neurofibromatosis 2
Intervention: Drug: RAD001
4 Unknown  Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Condition: Neurofibromatosis Type II
Intervention: Drug: Everolimus (RAD001) , Afinitor®
5 Active, not recruiting Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Neurofibromatosis 2;   Vestibular Schwannoma
Intervention: Drug: Lapatinib
6 Suspended PTC299 for Treatment of Neurofibromatosis Type 2
Condition: Neurofibromatosis 2
Intervention: Drug: PTC299
7 Completed Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Conditions: Acoustic Schwannoma;   Neurofibromatosis Type 2
Interventions: Biological: bevacizumab;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
8 Recruiting Neurofibromatosis (NF) Registry Portal
Conditions: Neurofibromatosis 1;   Neurofibromatosis 2;   Schwannomatosis
Intervention:
9 Recruiting Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Conditions: Neurofibromatosis Type 2;   Neuroma, Acoustic
Intervention: Drug: RAD001, everolimus
10 Recruiting Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Progressive Vestibular Schwannomas
Intervention: Drug: Bevacizumab
11 Completed An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
Condition: Neurofibromatosis 2
Intervention: Device: Penetrating auditory brainstem implant
12 Completed Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
Condition: Neurofibromatosis 2
Intervention: Device: Multichannel Auditory Brain Stem Implant
13 Active, not recruiting Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Conditions: Acoustic Schwannoma;   Adult Anaplastic Meningioma;   Adult Ependymoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Meningeal Hemangiopericytoma;   Adult Papillary Meningioma;   Neurofibromatosis Type 1;   Neurofibromatosis Type 2;   Recurrent Adult Brain Tumor
Intervention: Biological: bevacizumab
14 Unknown  NF2 Natural History Consortium
Conditions: Schwannoma, Vestibular;   Neurofibromatosis 2;   Meningioma
Intervention:
15 Active, not recruiting Natural History Study of Patients With Neurofibromatosis Type 2
Conditions: Spinal Cord Disease;   Intracranial Central Nervous System Disorder;   Neurologic Disorders;   Brain Neoplasms
Intervention:
16 Completed Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I
Conditions: Neurofibromatosis Type 1;   Von Recklinghausen Disease;   NF1
Intervention:
17 Recruiting Concentration and Activity of Lapatinib in Vestibular Schwannomas
Conditions: Vestibular Schwannoma;   NF2;   Neurofibromatosis 2;   Acoustic Neuroma;   Auditory Tumor
Intervention: Drug: lapatinib
18 Active, not recruiting Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Conditions: Neoplasms;   Nervous System Disease;   Vestibular Disease
Intervention:
19 Active, not recruiting Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma;   Neurofibromatoses
Intervention: Drug: RAD001: Everolimus
20 Recruiting Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas;   Meningiomas
Intervention: Drug: RAD001 10mg p.o. daily

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years